CGMP Violations at LGM Pharma Solutions

Share

A 5/11-5/18 FDA inspection at the LGM Pharma Solutions drug manufacturing facility in Irvine, CA, identified current good manufacturing practice (CGMP) violations in the firm’s manufacturing of finished drugs. An 11/2 Warning Letter says the specific violations were:

  • failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed; and
  • failure to establish adequate written procedures for production and process control designed to assure that manufactured drug products have the identity, strength, quality, and purity they purport or are represented to possess.

FDA acknowledges the firm’s commitment to cease production of redacted drug products at the facility and says LGM should contact the agency if it plans to resume any manufacturing operations for those drugs.

The letter says FDA recommends that the firm engage a qualified consultant to perform a comprehensive six-system audit of its entire operation for CGMP compliance, assist it in meeting CGMP requirements, and evaluate the completion and efficacy of its corrective and preventive actions before LGM pursues resolution of its compliance status with FDA.

The company was told to address the violations promptly and ensure that appropriate resources are allocated to fully address the violations and prevent their recurrence.

Read more